Torrent Pharmaceuticals Ltd (Torrent) focuses on chronic and sub-chronic therapeutic segments. It specializes in the manufacturing, marketing, and distribution of branded generics and generic pharmaceutical products, providing affordable alternatives to patented drugs. Torrent's product portfolio includes both generics and branded generics. The branded generics sector consists of the production and distribution of pharmaceutical products under Torrent’s brand names. These products offer cost-effective alternatives to patented drugs and cover a range of conditions such as Cardiovascular (CV), Central Nervous System (CNS), Gastrointestinal (GI), women's healthcare (WHC), Vitamin Mineral Nutrients (VMN), dermatology, diabetes, pain management, and gynecology. Torrent’s branded generics are available in India, Brazil, and select emerging markets where the company has established significant brand presence and recognition.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Torrent is committed to advancing its portfolio through cutting-edge research and development, with a focus on innovation and market expansion. In FY2025, Torrent was granted 38 NDDS patents, adding to its total of 689 patents out of 1,279 applications submitted to date. The company secured two key patents related to API/process/formulation. These included a novel process for an alternate polymorph and salt of an intermediate for FTF products, with a PCT application filed. There are 107 projects under development in the pipeline. The company collaborates with academic institutions such as IIT - Gandhinagar, BITS - Hyderabad, and SICART - Vallabh Vidyanagar for technology alliances. The company is also expanding its expertise in fixed-dose combinations (FDCs) of probiotics and enhancing its quality framework through advanced analytical technologies. Additionally, Torrent Pharmaceuticals Ltd is committed to adopting next-generation technologies to drive innovation and enhance operational efficiencies. Additionally, Torrent developed an improved and cost-effective process for an MAO-B inhibitor incorporating green chemistry principles and optimized the process for an antiepileptic drug using cheaper catalysts. A new, cost-effective API process for treating chronic idiopathic constipation was also developed. Torrent has made strategic advances in the consumer health care (CHC) segment and plans to file one oncology product in both the US and EU. The pipeline includes complex generics, injectables, and 505(b)(2) products aimed at addressing unmet medical needs. A complex generics product with CGT status was launched in the US market, featuring 180 days of exclusivity. The company’s state-of-the-art Bio-Evaluation Centre and research facility in Bhat, Gujarat, facilitates product development through comprehensive bioequivalence studies. This facility has recently been recertified by ANVISA (Brazil) until May 2025. Torrent has over 800 scientists and 167 support staff in its R&D activities. In FY2025, the company spent INR304.2 million on its research and development expenses, which as a percentage of revenue stood at 0.2%.